Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability PJM Brouwer, TG Caniels, K van der Straten, JL Snitselaar, Y Aldon, ... Science 369 (6504), 643-650, 2020 | 1162 | 2020 |
SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2 TM Clausen, DR Sandoval, CB Spliid, J Pihl, HR Perrett, CD Painter, ... Cell 183 (4), 1043-1057. e15, 2020 | 1030 | 2020 |
Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes SW De Taeye, G Ozorowski, AT de la Peña, M Guttman, JP Julien, ... Cell 163 (7), 1702-1715, 2015 | 338 | 2015 |
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate S Bangaru, G Ozorowski, HL Turner, A Antanasijevic, D Huang, X Wang, ... Science 370 (6520), 1089-1094, 2020 | 321 | 2020 |
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection G Song, W He, S Callaghan, F Anzanello, D Huang, J Ricketts, JL Torres, ... Nature communications 12 (1), 2938, 2021 | 272 | 2021 |
Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike G Ozorowski, J Pallesen, N de Val, D Lyumkis, CA Cottrell, JL Torres, ... Nature 547 (7663), 360-363, 2017 | 234 | 2017 |
Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies LE McCoy, MJ van Gils, G Ozorowski, T Messmer, B Briney, JE Voss, ... Cell reports 16 (9), 2327-2338, 2016 | 231 | 2016 |
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity H Liu, NC Wu, M Yuan, S Bangaru, JL Torres, TG Caniels, ... Immunity 53 (6), 1272-1280. e5, 2020 | 205 | 2020 |
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients E Andreano, E Nicastri, I Paciello, P Pileri, N Manganaro, G Piccini, ... Cell 184 (7), 1821-1835. e16, 2021 | 191 | 2021 |
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses JM Steichen, YC Lin, C Havenar-Daughton, S Pecetta, G Ozorowski, ... Science 366 (6470), eaax4380, 2019 | 176 | 2019 |
Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows D Sok, KM Le, M Vadnais, KL Saye-Francisco, JG Jardine, JL Torres, ... Nature 548 (7665), 108-111, 2017 | 170 | 2017 |
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain NC Wu, M Yuan, H Liu, CCD Lee, X Zhu, S Bangaru, JL Torres, ... Cell reports 33 (3), 2020 | 153 | 2020 |
Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization AT de la Pena, JP Julien, SW de Taeye, F Garces, M Guttman, ... Cell reports 20 (8), 1805-1817, 2017 | 147 | 2017 |
Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein D Oyen, JL Torres, U Wille-Reece, CF Ockenhouse, D Emerling, ... Proceedings of the National Academy of Sciences 114 (48), E10438-E10445, 2017 | 132 | 2017 |
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence K Sliepen, BW Han, I Bontjer, P Mooij, F Garces, AJ Behrens, ... Nature communications 10 (1), 2355, 2019 | 127 | 2019 |
Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability V Dubrovskaya, K Tran, G Ozorowski, J Guenaga, R Wilson, S Bale, ... Immunity 51 (5), 915-929. e7, 2019 | 122 | 2019 |
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer R Derking, G Ozorowski, K Sliepen, A Yasmeen, A Cupo, JL Torres, ... PLoS pathogens 11 (3), e1004767, 2015 | 114 | 2015 |
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects MF Jennewein, AJ MacCamy, NR Akins, J Feng, LJ Homad, NK Hurlburt, ... Cell reports 36 (2), 2021 | 98 | 2021 |
Long-primed germinal centres with enduring affinity maturation and clonal migration JH Lee, HJ Sutton, CA Cottrell, I Phung, G Ozorowski, LM Sewall, ... Nature 609 (7929), 998-1004, 2022 | 85 | 2022 |
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern H Cho, KK Gonzales-Wartz, D Huang, M Yuan, M Peterson, J Liang, ... Science translational medicine 13 (616), eabj5413, 2021 | 82 | 2021 |